Stock NEOP NEOPROBE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Neoprobe Corporation Nyse

Equities

NEOP

US6405181065

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Neoprobe Corporation
Jun. 21 Navidea Biopharmaceuticals, Inc. Announces Board Resignations CI
2023 Navidea Biopharmaceuticals, Inc. announced that it has received $0.75 million in funding CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Navidea Biopharmaceuticals, Inc. Announces Board Resignations
CI
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
AQ
Navidea Biopharmaceuticals, Inc. announced that it has received $0.75 million in funding
CI
Navidea: Q3 Earnings Snapshot
AQ
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Navidea Biopharmaceuticals, Inc.(OTCPK:NAVB) dropped from S&P TMI Index
CI
Sector Update: Health Care
MT
Top Midday Decliners
MT
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision
MT
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock
BU
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
BU
Navidea Biopharmaceuticals, Inc. Announces Resignation of Malcolm G. Witter as Director, Member of the Audit Committee and Compensation, Nominating and Governance Committee of the Board
CI
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
AQ
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
BU
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
BU
Navidea Biopharmaceuticals, Inc. Announces Executive Changes
CI
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
BU
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
CI
Navidea Biopharmaceuticals, Inc. Announces Board Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAVB Stock
  4. NEOP Stock
  5. News Neoprobe Corporation